论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Zeng Y, Ma J, Zhan Y, Xu X, Zeng Q, Liang J, Chen X
Received 1 June 2018
Accepted for publication 22 August 2018
Published 18 October 2018 Volume 2018:13 Pages 6551—6574
DOI https://doi.org/10.2147/IJN.S173431
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Lei Yang
Abstract: Hypoxia is one of the marked features of malignant tumors, which is
associated with several adaptation changes in the microenvironment of tumor
cells. Therefore, targeting tumor hypoxia is a research hotspot for cancer
therapy. In this review, we summarize the developing chemotherapeutic drugs for
targeting hypoxia, including quinones, nitroaromatic/nitroimidazole, N-oxides,
and transition metal complexes. In addition, redox-responsive bonds, such as
nitroimidazole groups, azo-groups, and disulfide bonds, are frequently used in
drug delivery systems for targeting the redox environment of tumors. Both
hypoxia-activated prodrugs and redox-responsive drug delivery nanocarriers have
significant effects on targeting tumor hypoxia for cancer therapy.
Hypoxia-activated prodrugs are commonly used in clinical trials with favorable
prospects, while redox-responsive nanocarriers are currently at the
experimental stage.
Keywords: antitumor drugs, hypoxia, nanoparticles, redox-sensitive, tumor therapy